Potential COPD Drug Receives Key Patent

PUR0200, a new inhaled drug being developed by Pulmatrix for the treatment of chronic obstructive pulmonary disease (COPD), has received a key patent in the United States, ensuring that it is protected by intellectual property until 2033.
________________________________________________________________________________________________________________________________________________________
RELATED CONTENT
Is Standard COPD Therapy Effective in Alpha-1 Antitrypsin Deficiency?
Study Examines Efficacy of Add-On Antibiotic for COPD Exacerbations
________________________________________________________________________________________________________________________________________________________

Pulmatrix designed PUR0200 to improve the administration of inhaled medication by engineering a dry powder with dense particles that are easily dispersed. The active ingredient— tiotropium bromide— is incorporated into the dry powder, making it more likely to reach the lungs and reduce the amount of medication that remains in the mouth and throat.

Clinical trials have shown that PUR0200 is well-tolerated and is approximately 5 times more efficient at delivering medication to the lungs than other products on the market.

"This new patent is another step forward to bringing PUR0200 to market—and to be able to offer new benefits to patients suffering from COPD," said Robert W Clarke, PhD, Chief Executive Officer at Pulmatrix.

—Melissa Weiss

Reference:

Pulmatrix receives key US patent for its inhaled drug for COPD [press release]. Lexington, MA; Pulmatrix; May 9, 2017. http://ir.pulmatrix.com/2017-05-09-Pulmatrix-Receives-Key-US-Patent-for-its-Inhaled-Drug-for-COPD.